AKT2

Across TCGA pan-cancer cohorts, AKT2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AKT2 data layer compared with 28 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher AKT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AKT2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

UCEC, CCRCC, and LSCC are the cancer types where AKT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.740	0.956	<.001	36	view →
CCRCC	DFS	Median	III,IV	0.928	0.128	.014	34	view →
LSCC	DFS	Median	II,III,IV	0.303	1.000	<.001	33	view →
PDAC	DFS	Tertile	II,III,IV	0.288	0.559	.005	16	view →
LUAD	DFS	Median	III,IV	0.263	0.744	.009	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AKT2–UCEC (DFS)

Open the UCEC breakdown →